Biozenta Lifescience Private Limited

Biozenta Lifescience Private Limited, established on February 22, 2018, is a privately held pharmaceutical company headquartered in Mumbai, Maharashtra, India. The company operates under the Corporate Identification Number (CIN) U74999MH2018PTC440022 and is registered with the Registrar of Companies (RoC) Mumbai. With an authorized capital of ₹1.00 crore and a paid-up capital of ₹60.00 lakh, Biozenta Lifescience has demonstrated significant growth since its inception. As of March 31, 2023, the company reported a revenue of $3.89 million USD, a net profit of $35,590 USD, and an EBITDA of $1.46 million USD.

The company's operations are managed by a team of directors, including Deep Narayan (Managing Director), Babita Saini, Abhishek Jain, Subodh Saini, Jainendra Kumar Sahu, and Sushil Kumar. As of January 9, 2026, Biozenta Lifescience employed approximately 55 professionals. The company's registered office is located at #7/54, Building No. 7, Anand Nagar Sahayog Cooperative Housing Society Ltd, Nehru Road, Mumbai, Maharashtra, 400055.

Biozenta Lifescience operates a state-of-the-art manufacturing facility in Una, Himachal Pradesh, India. This plant is WHO-cGMP certified and EU GMP approvable, specializing in the production of oncology products, including liquid and lyophilized injections, tablets, and capsules, as well as general injectables such as liquid and lyophilized injections and pre-filled syringes. The facility is strategically located to cater to both domestic and international markets, ensuring compliance with global quality standards.

The leadership team at Biozenta Lifescience is spearheaded by Managing Director Deep Narayan, who has been instrumental in the company's growth and strategic direction since its inception. Other key executives include Babita Saini, Abhishek Jain, Subodh Saini, Jainendra Kumar Sahu, and Sushil Kumar, each contributing to the company's diverse operations and expansion efforts. Their collective expertise in pharmaceutical manufacturing, regulatory affairs, and international business development has been pivotal in establishing Biozenta Lifescience as a competitive player in the global pharmaceutical industry.

Biozenta Lifescience has made significant strides in penetrating regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facility in Una, Himachal Pradesh, is WHO-cGMP certified and EU GMP approvable, indicating adherence to international quality standards. Additionally, Biozenta has secured product registrations in over 30 countries across Asia, Africa, Europe, Latin America, and the GCC, with more than 180 international product registrations. These certifications and registrations facilitate market access and underscore the company's commitment to quality and regulatory compliance.

Biozenta Lifescience has strategically expanded its presence in emerging markets, including Africa, Latin America, and Southeast Asia. The company's WHO-cGMP certified facility and EU GMP approvable status enable it to meet the stringent regulatory requirements of these regions. By obtaining product registrations in over 30 countries, Biozenta has enhanced its ability to participate in government tenders and supply to public health programs, thereby increasing its footprint in these emerging markets.

Biozenta Lifescience's geographic strategy reflects a balanced approach between diversification and concentration. While the company has established a strong presence in regulated markets such as the US, EU, UK, Australia, and Japan, it has also made significant inroads into emerging markets across Asia, Africa, Europe, Latin America, and the GCC. This dual approach mitigates concentration risk and positions Biozenta to leverage growth opportunities in diverse regions. The company's strategic direction focuses on expanding its global footprint while maintaining high standards of quality and compliance.

As of March 28, 2026, Biozenta Lifescience has not publicly disclosed specific details regarding FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection history. The company's focus on WHO-cGMP certification and EU GMP approvable status suggests a commitment to meeting international quality standards, which may facilitate future FDA approvals. However, without explicit information, a comprehensive assessment of Biozenta's FDA status cannot be provided.

Biozenta Lifescience's manufacturing facility in Una, Himachal Pradesh, is WHO-cGMP certified and EU GMP approvable, indicating compliance with international quality standards. These certifications are crucial for market access in regulated regions and reflect the company's commitment to maintaining high manufacturing standards. The EU GMP approvable status further enhances Biozenta's credibility in the European market, positioning it favorably for future collaborations and market expansion.

Biozenta Lifescience operates under the regulatory oversight of the Central Drugs Standard Control Organisation (CDSCO) in India. The company's manufacturing facility in Una, Himachal Pradesh, is WHO-cGMP certified and EU GMP approvable, indicating adherence to international quality standards. While specific details regarding CDSCO manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly disclosed, the company's compliance with global standards suggests alignment with Indian regulatory requirements.

As of March 28, 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to Biozenta Lifescience by regulatory authorities. The company's adherence to WHO-cGMP and EU GMP standards suggests a proactive approach to regulatory compliance. However, without explicit records, a detailed analysis of recent regulatory actions cannot be provided.

In the oncology pharmaceutical sector, Biozenta Lifescience faces competition from both domestic and international manufacturers. Key competitors include established Indian pharmaceutical companies with a strong presence in oncology products, as well as multinational corporations operating in the same therapeutic area. While specific market share data is not publicly available, Biozenta's focus on high-quality, affordable oncology medicines positions it as a competitive player in the market. The company's WHO-cGMP certified facility and EU GMP approvable status further enhance its competitive edge.

Biozenta Lifescience's key differentiators include its commitment to innovation, quality, and global reach. The company's manufacturing facility in Una, Himachal Pradesh, is WHO-cGMP certified and EU GMP approvable, ensuring adherence to international quality standards. Additionally, Biozenta has secured product registrations in over 30 countries, with more than 180 international product registrations, reflecting its extensive global presence. These factors collectively contribute to Biozenta's competitive advantages in the pharmaceutical industry.

Biozenta Lifescience's current strategic direction focuses on expanding its global footprint while maintaining high standards of quality and compliance. The company's portfolio includes oncology, critical care, APIs, and general injectables, indicating a diversified approach to pharmaceutical manufacturing. Future outlooks suggest continued growth in both regulated and emerging markets, leveraging its WHO-cGMP certified and EU GMP approvable manufacturing facility. The company's commitment to innovation and quality positions it favorably for sustained success in the global pharmaceutical industry.

Biozenta Lifescience has demonstrated a strong track record in pharmaceutical manufacturing, with a focus on oncology and critical care products. The company's manufacturing facility in Una, Himachal Pradesh, is WHO-cGMP certified and EU GMP approvable, indicating adherence to international quality standards. While specific export volumes and consistency metrics are not publicly disclosed, the company's product registrations in over 30 countries and more than 180 international product registrations suggest a reliable and consistent export performance. These factors collectively indicate Biozenta's reliability as a pharmaceutical supplier.

Importers should verify the following certifications when considering Biozenta Lifescience as a supplier:

• WHO-cGMP Certification: Confirms compliance with World Health Organization